Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Late-Stage Trials Pose Challenge As FDA Molds Adaptive Design Guidance

Executive Summary

The work group developing FDA's guidance on adaptive clinical trial design is still trying to figure out the complex issues associated with late-stage studies, the Center for Drug Evaluation and Research's "town hall" discussion at the Drug Information Association annual meeting in Atlanta revealed

You may also be interested in...



EMEA Looking At Limited Use Of Adaptive Design In Late-Stage Trials

Adaptive designs are "a contradiction to the confirmatory nature" of Phase III clinical trials, EMEA's Committee for Medicinal Products for Human Use says in a reflection paper

EMEA Looking At Limited Use Of Adaptive Design In Late-Stage Trials

Adaptive designs are "a contradiction to the confirmatory nature" of Phase III clinical trials, EMEA's Committee for Medicinal Products for Human Use says in a reflection paper

FDA Is Waiting On Internal Analysis Of Avandia Cardiovascular Safety Signal

FDA is not taking immediate regulatory action on an observed cardiovascular signal for GlaxoSmithKline's Avandia, as the agency feels the current labeling is sufficient until its own analysis of emerging safety data for the type 2 diabetes therapy is completed

Related Content

Latest News
See All
UsernamePublicRestriction

Register

PS048569

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel